CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
NCT04661020
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Large B-Cell Lymphoma (LBCL)
Interventions
DRUG:
CD19 CAR-T cells
Sponsor
Zhejiang University
Collaborators
[object Object]